LGND vs. ELAN
LGND (Ligand Pharmaceuticals Incorporated) and ELAN (Elanco Animal Health Incorporated) are both stocks. Both are in the Healthcare sector — LGND in Biotechnology, ELAN in Drug Manufacturers - Specialty & Generic. Over the past 5 years, LGND returned 21.24%/yr vs -5.40%/yr for ELAN. At a 0.28 correlation, their price movements are largely independent.
Performance
LGND vs. ELAN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LGND achieves a 56.79% return, which is significantly higher than ELAN's 14.67% return.
LGND
- 1D
- 0.06%
- 1M
- 16.14%
- 6M
- 51.19%
- YTD
- 56.79%
- 1Y
- 128.69%
- 3Y*
- 62.76%
- 5Y*
- 21.24%
- 10Y*
- 8.93%
ELAN
- 1D
- 1.61%
- 1M
- 7.10%
- 6M
- 7.32%
- YTD
- 14.67%
- 1Y
- 78.84%
- 3Y*
- 31.09%
- 5Y*
- -5.40%
- 10Y*
- —
LGND vs. ELAN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
LGND Ligand Pharmaceuticals Incorporated | 56.79% | 76.45% | 50.03% | 6.92% | -56.75% | 55.31% | -4.64% | -23.15% | -48.63% |
ELAN Elanco Animal Health Incorporated | 14.67% | 86.87% | -18.72% | 21.93% | -56.94% | -7.47% | 4.14% | -6.60% | -2.23% |
Correlation
The correlation between LGND and ELAN is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.28 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Sep 20, 2018 | 0.28 |
Fundamentals
LGND:
$5.94B
ELAN:
$12.97B
LGND:
$7.53
ELAN:
-$0.48
LGND:
22.03
ELAN:
2.65
LGND:
5.91
ELAN:
2.02
LGND:
$274.48M
ELAN:
$4.89B
LGND:
$221.02M
ELAN:
$2.42B
LGND:
$253.90M
ELAN:
$755.00M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LGND vs. ELAN — Risk / Return Rank
LGND
ELAN
LGND vs. ELAN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ligand Pharmaceuticals Incorporated (LGND) and Elanco Animal Health Incorporated (ELAN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LGND | ELAN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.71 | ||
| Sortino ratioReturn per unit of downside risk | +1.32 | ||
| Omega ratioGain probability vs. loss probability | 1.51 | 1.33 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 9.20 | 3.02 | +6.18 |
| Martin ratioReturn relative to average drawdown | 23.02 | 9.31 | +13.71 |
Loading charts...
Drawdowns
LGND vs. ELAN - Drawdown Comparison
The maximum LGND drawdown since its inception was -93.34%, which is greater than ELAN's maximum drawdown of -78.00%. Use the drawdown chart below to compare losses from any high point for LGND and ELAN.
Loading charts...
Drawdown Indicators
| LGND | ELAN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.34% | -78.00% | -15.34% |
Max Drawdown (1Y)Largest decline over 1 year | -14.07% | -26.23% | +12.16% |
Max Drawdown (3Y)Largest decline over 3 years | -29.91% | -56.10% | +26.19% |
Max Drawdown (5Y)Largest decline over 5 years | -70.11% | -78.00% | +7.89% |
Max Drawdown (10Y)Largest decline over 10 years | -81.94% | — | — |
Current DrawdownCurrent decline from peak | -8.11% | -29.33% | +21.22% |
Average DrawdownAverage peak-to-trough decline | -44.43% | -39.70% | -4.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.61% | 8.50% | -2.89% |
Volatility
LGND vs. ELAN - Volatility Comparison
Ligand Pharmaceuticals Incorporated (LGND) has a higher volatility of 12.60% compared to Elanco Animal Health Incorporated (ELAN) at 9.11%. This indicates that LGND's price experiences larger fluctuations and is considered to be riskier than ELAN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LGND | ELAN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.60% | 9.11% | +3.49% |
Volatility (6M)Calculated over the trailing 6-month period | 28.19% | 33.57% | -5.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 37.25% | 44.33% | -7.08% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 44.15% | 45.86% | -1.71% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 45.46% | 44.33% | +1.13% |
Dividends
LGND vs. ELAN - Dividend Comparison
Neither LGND nor ELAN has paid dividends to shareholders.
Financials
LGND vs. ELAN - Financials Comparison
This section allows you to compare key financial metrics between Ligand Pharmaceuticals Incorporated and Elanco Animal Health Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LGND vs. ELAN - Profitability Comparison
LGND - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Ligand Pharmaceuticals Incorporated reported a gross profit of 0.00 and revenue of 51.72M. Therefore, the gross margin over that period was 0.0%.
ELAN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Elanco Animal Health Incorporated reported a gross profit of 785.00M and revenue of 1.37B. Therefore, the gross margin over that period was 57.3%.
LGND - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Ligand Pharmaceuticals Incorporated reported an operating income of 17.37M and revenue of 51.72M, resulting in an operating margin of 33.6%.
ELAN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Elanco Animal Health Incorporated reported an operating income of 307.00M and revenue of 1.37B, resulting in an operating margin of 22.4%.
LGND - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Ligand Pharmaceuticals Incorporated reported a net income of -13.35M and revenue of 51.72M, resulting in a net margin of -25.8%.
ELAN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Elanco Animal Health Incorporated reported a net income of 57.00M and revenue of 1.37B, resulting in a net margin of 4.2%.
Frequently Asked Questions
LGND and ELAN have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LGND has higher volatility (12.60%) compared to ELAN (9.11%). In terms of maximum drawdown, LGND dropped -93.34% vs ELAN's -78.00%.
LGND currently has the higher Sharpe Ratio (3.49 vs 1.79), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LGND and ELAN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer